Director MacLeod buys 143,000 ZOM shares at $0.06; 7 other insiders bought within 14 days as stock down 22.7% in 90 days
Christopher Ross, a director, purchased 143,000 shares at $0.06 on March 17, 2025, his first holdings at Zomedica. The transaction is notable for occurring within a cluster pattern: 7 other insiders also bought within the past 14 days. The company is unprofitable with net income of $-6.7M against revenue of $7.0M (latest quarter), and the stock is down 22.7% over 90 days and 44.4% from its 52-week high of $0.18. The coordinated buying activity by multiple insiders at depressed levels following significant recent losses suggests alignment among the board and management despite the company's current unprofitable state and deteriorating stock performance.